[O2Micro Revises Third Quarter 2012 Financial Guidance 2 GEORGE TOWN, Grandyman, Oct. 3, 2012 (GLOBE NEWSWIRE) -- O The reduction in anticipated revenue for the third quarter is primarily the result of broad-based weakness in demand in thempany's end markets. 2 2 2 Sterling Du, Chairman and CEO of O]
[TPI Reports Fiscal Year 2012 Financial Results CHENGDU, China, September 28, 2012 Tianyin Pharmaceutical Inc. (NYSE Amex: TPI), a pharmaceutical company that specializes in the patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded generics and active pharmaceutical ingredients (API) announced financial results for the fiscal year 2012. Fiscal Year 2012 Ended June 30, 2012 Financial Highlights: ● FY2012 revenue delivered] [Tianyin Pharmaceutical Co., Inc. Fiscal 2012 Earnings Call September 28, 2012 Operator: I would now like to turn the conference over to our host, Dr. James Tong, Chief Financial Officer. Please go ahead, sir. Dr. James Tong: Fiscal year 2012 financial highlights. Revenue delivered $69.6 million, compared with $95.2 million in fiscal year 2011. Operating income delivered $8.5 million, compared] [CURRENT REPORT FOR ISSUERS SUBJECT TO THE FORM 8-K CURRENT REPORT September 28, 2012 Date of Report (Date of Earliest Event Reported) Tianyin Pharmaceutical Co, Inc. Delaware 000-52236 20-4857782 (State or other jurisdiction of incorporation) (IRS Employer Identification No.) 23rd Floor, Unionsun Yangkuo Plaza, No. 2, Block 3 South Renmin Road Chengdu, P. R. China, 610041 +011-86-28-8615-4737 o o o]
[O2Micro Revises Third Quarter 2012 Financial Guidance 2 GEORGE TOWN, Grandyman, Oct. 3, 2012 (GLOBE NEWSWIRE) -- O The reduction in anticipated revenue for the third quarter is primarily the result of broad-based weakness in demand in thempany's end markets. 2 2 2 Sterling Du, Chairman and CEO of O]
[TPI Reports Fiscal Year 2012 Financial Results CHENGDU, China, September 28, 2012 Tianyin Pharmaceutical Inc. (NYSE Amex: TPI), a pharmaceutical company that specializes in the patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded generics and active pharmaceutical ingredients (API) announced financial results for the fiscal year 2012. Fiscal Year 2012 Ended June 30, 2012 Financial Highlights: ● FY2012 revenue delivered] [Tianyin Pharmaceutical Co., Inc. Fiscal 2012 Earnings Call September 28, 2012 Operator: I would now like to turn the conference over to our host, Dr. James Tong, Chief Financial Officer. Please go ahead, sir. Dr. James Tong: Fiscal year 2012 financial highlights. Revenue delivered $69.6 million, compared with $95.2 million in fiscal year 2011. Operating income delivered $8.5 million, compared] [CURRENT REPORT FOR ISSUERS SUBJECT TO THE FORM 8-K CURRENT REPORT September 28, 2012 Date of Report (Date of Earliest Event Reported) Tianyin Pharmaceutical Co, Inc. Delaware 000-52236 20-4857782 (State or other jurisdiction of incorporation) (IRS Employer Identification No.) 23rd Floor, Unionsun Yangkuo Plaza, No. 2, Block 3 South Renmin Road Chengdu, P. R. China, 610041 +011-86-28-8615-4737 o o o]
[October 3, 2012 H. Roger Schwall Jennifer OBrien Ethan Horowitz Division of Corporate Finance 100 F Street, NE Re: PetroChina Company Limited Form 20-F for Fiscal Year Ended December 31, 2011 Filed April 26, 2012 Comment Letter Dated September 21, 2012 File No. 001-15006 Dear Mr. Schwall, Ms. OBrien and Mr. Horowitz: We are in the process of collecting the]
[October 3, 2012 H. Roger Schwall Jennifer OBrien Ethan Horowitz Division of Corporate Finance 100 F Street, NE Re: PetroChina Company Limited Form 20-F for Fiscal Year Ended December 31, 2011 Filed April 26, 2012 Comment Letter Dated September 21, 2012 File No. 001-15006 Dear Mr. Schwall, Ms. OBrien and Mr. Horowitz: We are in the process of collecting the]
[Item 1: Reporting Person - FMR LLC Item 4: Delaware Item 5: 5,882,315 Item 6: 0 Item 7: 6,569,315 Item 8: 0 Item 9: 6,569,315 Item 11: 14.104% Item 12: HC Cusip #64118U926 Item 1: Reporting Person - Edward C. Johnson 3d Item 5: 0 Item 6: 0 Item 7: 6,569,315 Item 8: 0 Item 9: 6,569,315 Item 11: 14.104%]
[Item 1: Reporting Person - FMR LLC Item 4: Delaware Item 5: 5,882,315 Item 6: 0 Item 7: 6,569,315 Item 8: 0 Item 9: 6,569,315 Item 11: 14.104% Item 12: HC Cusip #64118U926 Item 1: Reporting Person - Edward C. Johnson 3d Item 5: 0 Item 6: 0 Item 7: 6,569,315 Item 8: 0 Item 9: 6,569,315 Item 11: 14.104%]
